Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
House dust mite-specific immunoglobulin G4 (HDM-specific IgG4) is a specialized subclass of antibodies produced by B cells in response to prolonged or high-dose exposure to allergens from the dust mite species Dermatophagoides pteronyssinus and Dermatophagoides farinae. In the context of allergic disease, these antibodies serve a protective role by acting as 'blocking antibodies' that compete with allergen-specific IgE for binding to major HDM allergens such as Der p 1, Der p 2, and Der f 1 (PMID: 30103933). By intercepting these allergens, IgG4 prevents the cross-linking of IgE bound to mast cells and basophils, which otherwise triggers the release of inflammatory mediators like histamine and leukotrienes (PMID: 28212950). Beyond simple neutralization, HDM-specific IgG4 also inhibits IgE-facilitated antigen presentation to T cells, thereby dampening the overall Th2-mediated allergic cascade (PMID: 21834850). The induction of high levels of HDM-specific IgG4 is a primary goal and a key biomarker of clinical efficacy in allergen immunotherapy (AIT), signaling a shift toward immunological tolerance. Therapeutic products such as Acarizax and Odactra are specifically designed to stimulate the production of these antibodies to provide long-term relief from allergic rhinitis and asthma symptoms.
Induction of allergen-specific IgG4 antibodies that act as blocking antibodies to compete with IgE for allergen binding sites, thereby preventing the cross-linking of high-affinity IgE receptors (FcεRI) on mast cells and basophils (PMID: 28212950, PMID: 21834850).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on House dust mite-specific immunoglobulin G4 (HDM-specific IgG4) (HDM-specific IgG4).